Industry says manufacturers have 2-4 weeks of buffer stocks, but prolonged disruption could push up shortage risks, especially of consumables like IV and syringes.
On the sidelines of the Bio Asia event in Hyderabad, BIRAC MD Jitendra Kumar says biotechnology department is planning the sandboxes to 'reduce regulatory uncertainty'.
India’s pharma industry relies heavily on US market, with $8.07 bn worth of exports in FY 2023-2024. Pharmaceuticals are India’s third largest goods exported to US in dollar terms.
Researchers associated with The Ohio State University found that number of severe adverse events linked to generic drugs made in India was 54% higher than for those made in the US.
India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.
Report by Organisation of Pharmaceutical Producers of India and Ernst & Young says growth could be propelled by expansion in the domestic market, spurred by India's economic growth.
Nearly 80 percent of small and medium drug manufacturing units in India do not follow good manufacturing practices (GMP) requirements, according to government estimates.
The Drugs, Medical Devices and Cosmetics Bill, 2023, is being planned as a substitute for the existing drug law, which was passed during the pre-Independence period.
Industry says manufacturers have 2-4 weeks of buffer stocks, but prolonged disruption could push up shortage risks, especially of consumables like IV and syringes.
French newspaper La Tribune earlier last week indicated that UAE withdrew from deal to fund EUR 3.5 billion. India is looking to order 114 new Rafales, which could include the F5.
China patiently invested capital, skill and technology in coal gasification. Unlike it, we won’t move from words to action. As crude prices decline, we lose interest.
COMMENTS